HK1126761A1 - Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation - Google Patents

Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation

Info

Publication number
HK1126761A1
HK1126761A1 HK09105576.2A HK09105576A HK1126761A1 HK 1126761 A1 HK1126761 A1 HK 1126761A1 HK 09105576 A HK09105576 A HK 09105576A HK 1126761 A1 HK1126761 A1 HK 1126761A1
Authority
HK
Hong Kong
Prior art keywords
processes
preparation
treatment
enantiomerically pure
proliferative disorders
Prior art date
Application number
HK09105576.2A
Other languages
English (en)
Chinese (zh)
Inventor
Meenakshi Sivakumar
Malcolm Mascarenhas
Ankush Sarde
Pramod Kumar Jadhav
Manoj Shukla
Kalpana Joshi
Maggie Rathos
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of HK1126761A1 publication Critical patent/HK1126761A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09105576.2A 2006-06-21 2009-06-22 Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation HK1126761A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/052002 WO2007148158A1 (en) 2006-06-21 2006-06-21 Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation

Publications (1)

Publication Number Publication Date
HK1126761A1 true HK1126761A1 (en) 2009-09-11

Family

ID=37744533

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105576.2A HK1126761A1 (en) 2006-06-21 2009-06-22 Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation

Country Status (19)

Country Link
US (1) US8563596B2 (xx)
EP (1) EP2046738B1 (xx)
JP (1) JP5498782B2 (xx)
KR (1) KR101209397B1 (xx)
CN (1) CN101472888B (xx)
AR (1) AR061567A1 (xx)
AU (1) AU2006344987B8 (xx)
BR (1) BRPI0621777A2 (xx)
CA (1) CA2655789C (xx)
DK (1) DK2046738T3 (xx)
ES (1) ES2491140T3 (xx)
HK (1) HK1126761A1 (xx)
IL (1) IL195850A0 (xx)
MX (1) MX2008016398A (xx)
NZ (1) NZ574266A (xx)
PT (1) PT2046738E (xx)
TW (1) TWI461420B (xx)
WO (1) WO2007148158A1 (xx)
ZA (1) ZA200810756B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
BRPI0621851A2 (pt) 2006-07-07 2013-01-29 Piramal Life Sciences Ltd sÍntese enantiosseletiva de pirrolidinas substituÍdas com flavonas, e intermediÁrios das mesmas
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
EP2544686A4 (en) 2010-02-05 2013-06-26 Whitehead Biomedical Inst COMBINED METHODS FOR THE TREATMENT OF DISEASES
JP2013520484A (ja) * 2010-02-26 2013-06-06 ピラマル エンタープライジーズ リミテッド 炎症性疾患の治療のためのピロリジン置換フラボン
WO2011121505A1 (en) 2010-03-29 2011-10-06 Piramal Life Sciences Limited Cytokine inhibitors
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
EP2723449A2 (en) 2011-06-24 2014-04-30 Piramal Enterprises Limited Compounds for the treatment of cancers associated with human papillomavirus
WO2013105056A1 (en) 2012-01-13 2013-07-18 Piramal Enterprises Limited Pyrrolidine- substituted flavone derivatives for prevention or treatment of oral mucositis
EP2877461B1 (en) 2012-07-27 2018-05-09 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
KR101389407B1 (ko) * 2012-08-27 2014-05-27 한림대학교 산학협력단 척추 고정용 임플란트
WO2014049515A1 (en) * 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
AU2013337742B2 (en) 2012-11-05 2017-11-23 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2014128524A1 (en) * 2013-02-19 2014-08-28 Piramal Enterprises Limited An improved process for preparation of an intermediate of the pyrrolidine substituted flavones
WO2014128523A1 (en) * 2013-02-19 2014-08-28 Piramal Enterprises Limited A process for preparation of an intermediate of the pyrrolidine substituted flavones
WO2014140695A1 (en) * 2013-03-15 2014-09-18 Piramal Enterprises Limited Solid oral formulation of a pyrrolidine substituted flavone compound
WO2015004636A1 (en) * 2013-07-12 2015-01-15 Piramal Enterprises Limited A pharmaceutical combination for the treatment of melanoma
US10555931B2 (en) 2014-05-28 2020-02-11 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
KR102275758B1 (ko) 2016-03-28 2021-07-12 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
EP4344743A3 (en) 2018-08-07 2024-06-19 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
WO2020036995A1 (en) * 2018-08-14 2020-02-20 Mei Pharma, Inc. Combination therapy
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CA3136599A1 (en) * 2019-04-11 2020-10-15 Mei Pharma, Inc. Voruciclib poly morphs and methods of making and using thereof
CN110028475B (zh) * 2019-05-13 2022-07-01 中国药科大学 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用
CN114957182B (zh) * 2022-03-30 2024-03-15 中国药科大学 一类含有黄酮骨架结构的usp8抑制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (xx) 1986-04-11 1989-02-04 Hoechst India
JP3451099B2 (ja) 1991-12-06 2003-09-29 株式会社日立製作所 外部記憶サブシステム
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
CA2655789A1 (en) 2007-12-27
IL195850A0 (en) 2009-09-01
US8563596B2 (en) 2013-10-22
TWI461420B (zh) 2014-11-21
ES2491140T3 (es) 2014-09-05
US20100179210A1 (en) 2010-07-15
MX2008016398A (es) 2009-01-21
AU2006344987A2 (en) 2009-01-29
NZ574266A (en) 2011-10-28
AU2006344987A1 (en) 2007-12-27
EP2046738A1 (en) 2009-04-15
BRPI0621777A2 (pt) 2013-03-12
AR061567A1 (es) 2008-09-03
KR101209397B1 (ko) 2012-12-06
TW200813030A (en) 2008-03-16
KR20090023705A (ko) 2009-03-05
DK2046738T3 (da) 2014-08-04
JP5498782B2 (ja) 2014-05-21
AU2006344987B8 (en) 2013-07-11
CN101472888A (zh) 2009-07-01
JP2009541294A (ja) 2009-11-26
CN101472888B (zh) 2014-02-26
PT2046738E (pt) 2014-08-29
EP2046738B1 (en) 2014-06-11
ZA200810756B (en) 2013-05-29
WO2007148158A1 (en) 2007-12-27
AU2006344987B2 (en) 2012-11-15
CA2655789C (en) 2014-04-01

Similar Documents

Publication Publication Date Title
IL195850A0 (en) Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL200862A0 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
LT2229369T (lt) 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui
ZA200901523B (en) Use of extracts for the treatment of viral disorders
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
GB0909297D0 (en) Composition for the treatment of skin conditions
IL177609A0 (en) Inhibition of ornithine aminotransferase for the treatment of proliferative disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
EP2142566A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
IL211641A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych